We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
Ecolab's Q3 2026 revenues rose 13% to $4.69B, while adjusted EPS increased 5% to $2.18.
Global High-Tech organic sales surged 63% in Q3, with Ecolab targeting more than $4B in sales by 2030.
Ecolab's digital sales jumped 34% in Q3, but elevated costs drove a 70-basis-point gross margin decline.
Ecolab Inc. (ECL - Free Report) has been gaining from its solid product portfolio. The optimism, led by a decent third-quarter 2026 performance and continued focus on research and development, is expected to contribute further. However, concerns regarding cost fluctuations persist.
This Zacks Rank #3 (Hold) stock has gained 13.3% in the year-to-date period compared with the industry’s 10.6% growth. The S&P 500 Composite has increased 3.7% during the same time frame.
The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $84.3 billion. It projects 12.6% growth for the next five years and expects to maintain a strong performance in the future. Ecolab’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, and met twice, delivering an average surprise of 0.36%.
Image Source: Zacks Investment Research
Reasons Favoring Ecolab’s Growth
Ecolab’s Global High-Tech Business & Digital Platform: Ecolab's Global High-Tech business is emerging as a significant growth driver, benefiting from rising semiconductor manufacturing and AI-driven data-center investments. Organic sales surged 63% in the third quarter of 2026, while fixed-currency sales jumped 293%, supported by the acquisitions of Ovivo Electronics and CoolIT Systems. These acquisitions expand Ecolab's capabilities across ultrapure water purification, liquid cooling, coolant chemistry and digital monitoring.
CoolIT more than doubled sales on a pro forma basis, while Ovivo delivered double-digit growth against its pre-acquisition sales base. The integration of CoolIT's cooling platforms with Ecolab's 3D TRASAR technology and Ovivo's ultrapure water solutions strengthens its ability to deliver integrated solutions that improve operating efficiency while reducing water and energy consumption.
Management targets Global High-Tech sales of more than $4 billion by 2030, with annual growth exceeding 25% and an operating income margin of 25%. The business is also expected to contribute more than 2 percentage points to Ecolab's overall sales growth rate one year after the acquisitions close.
Early-stage cross-selling opportunities, alongside increasing adoption of digital monitoring and water-management solutions, provide additional growth avenues. The combination of a broader technology portfolio, expanding customer demand and integrated hardware, chemistry and analytics capabilities positions Ecolab to capitalize on long-term growth opportunities in semiconductor manufacturing and AI infrastructure.
Strong Product Portfolio With a Focus on R&D: Ecolab's diversified portfolio across water treatment, hygiene, life sciences, digital solutions and pest elimination provides a competitive advantage in addressing growing customer needs. The global water treatment systems market is projected to reach $48.5 billion in 2026 and expand at a CAGR of 8.9% through 2033, creating favorable growth opportunities.
In the third quarter of 2026, organic sales grew 7%, accelerating from 5% in the second quarter and 4% in the first quarter. Pricing contributed 5 percentage points, while volume growth improved to 2%, reflecting stronger underlying demand despite geopolitical disruptions.
Digital solutions are emerging as another important growth driver, with sales increasing 34% in the third quarter compared with 27% in the preceding quarter. Products like DishIQ, AquaIQ, KitchenIQ and ECOLAB3D help customers improve operational efficiency through connected monitoring, analytics and automation.
Management expects Digital to deliver long-term sales growth of more than 20%. Meanwhile, Ecolab's Pest Intelligence platform had more than 800,000 connected devices deployed by the third quarter, enabling continuous monitoring and predictive insights. The platform delivers nearly 99% pest-free environments compared with the industry standard of 94%, strengthening customer value and supporting recurring growth opportunities.
Decent Q3 Results: ECL reported third-quarter 2026 adjusted earnings of $2.18 per share, up 5% year over year. The figure was in line with the Zacks Consensus Estimate.
Revenues rose 13% year over year to $4.69 billion, surpassing the consensus estimate by 0.4%. Organic sales increased 7%. Volume growth accelerated to 2%, and pricing improved to 5%. Strong demand across Global High-Tech and Life Sciences supported the performance.
A Factor That May Offset ECL’s Gains
Cost Fluctuations: Ecolab continues to face cost pressures from elevated raw material, energy and transportation expenses, exacerbated by geopolitical disruptions in the Middle East. Although pricing improved to 5% in the third quarter from 4% in the preceding quarter, reported gross margin contracted 70 basis points year over year to 44.1%, while organic gross margin expanded just 10 basis points to 44.9%.
Management expects commodity costs to remain elevated and is relying on pricing actions, productivity gains and supply-chain efficiencies to offset inflation. For the fourth quarter of 2026, Ecolab expects an adjusted operating income margin of approximately 19% and an organic operating income margin of 20%. However, persistent cost inflation and delays in pricing recovery could weigh on profitability and limit further margin expansion.
Estimate Trend
Ecolab is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has remained stable at $8.16 per share.
The Zacks Consensus Estimate for the company’s fourth-quarter 2026 revenues is pegged at $4.75 billion, indicating a 13.1% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.
Image: Bigstock
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
Key Takeaways
Ecolab Inc. (ECL - Free Report) has been gaining from its solid product portfolio. The optimism, led by a decent third-quarter 2026 performance and continued focus on research and development, is expected to contribute further. However, concerns regarding cost fluctuations persist.
This Zacks Rank #3 (Hold) stock has gained 13.3% in the year-to-date period compared with the industry’s 10.6% growth. The S&P 500 Composite has increased 3.7% during the same time frame.
The renowned water, hygiene and infection prevention solutions and services provider has a market capitalization of $84.3 billion. It projects 12.6% growth for the next five years and expects to maintain a strong performance in the future. Ecolab’s earnings surpassed the Zacks Consensus Estimate in two of the trailing four quarters, and met twice, delivering an average surprise of 0.36%.
Image Source: Zacks Investment Research
Reasons Favoring Ecolab’s Growth
Ecolab’s Global High-Tech Business & Digital Platform: Ecolab's Global High-Tech business is emerging as a significant growth driver, benefiting from rising semiconductor manufacturing and AI-driven data-center investments. Organic sales surged 63% in the third quarter of 2026, while fixed-currency sales jumped 293%, supported by the acquisitions of Ovivo Electronics and CoolIT Systems. These acquisitions expand Ecolab's capabilities across ultrapure water purification, liquid cooling, coolant chemistry and digital monitoring.
CoolIT more than doubled sales on a pro forma basis, while Ovivo delivered double-digit growth against its pre-acquisition sales base. The integration of CoolIT's cooling platforms with Ecolab's 3D TRASAR technology and Ovivo's ultrapure water solutions strengthens its ability to deliver integrated solutions that improve operating efficiency while reducing water and energy consumption.
Management targets Global High-Tech sales of more than $4 billion by 2030, with annual growth exceeding 25% and an operating income margin of 25%. The business is also expected to contribute more than 2 percentage points to Ecolab's overall sales growth rate one year after the acquisitions close.
Early-stage cross-selling opportunities, alongside increasing adoption of digital monitoring and water-management solutions, provide additional growth avenues. The combination of a broader technology portfolio, expanding customer demand and integrated hardware, chemistry and analytics capabilities positions Ecolab to capitalize on long-term growth opportunities in semiconductor manufacturing and AI infrastructure.
Strong Product Portfolio With a Focus on R&D: Ecolab's diversified portfolio across water treatment, hygiene, life sciences, digital solutions and pest elimination provides a competitive advantage in addressing growing customer needs. The global water treatment systems market is projected to reach $48.5 billion in 2026 and expand at a CAGR of 8.9% through 2033, creating favorable growth opportunities.
In the third quarter of 2026, organic sales grew 7%, accelerating from 5% in the second quarter and 4% in the first quarter. Pricing contributed 5 percentage points, while volume growth improved to 2%, reflecting stronger underlying demand despite geopolitical disruptions.
Digital solutions are emerging as another important growth driver, with sales increasing 34% in the third quarter compared with 27% in the preceding quarter. Products like DishIQ, AquaIQ, KitchenIQ and ECOLAB3D help customers improve operational efficiency through connected monitoring, analytics and automation.
Management expects Digital to deliver long-term sales growth of more than 20%. Meanwhile, Ecolab's Pest Intelligence platform had more than 800,000 connected devices deployed by the third quarter, enabling continuous monitoring and predictive insights. The platform delivers nearly 99% pest-free environments compared with the industry standard of 94%, strengthening customer value and supporting recurring growth opportunities.
Decent Q3 Results: ECL reported third-quarter 2026 adjusted earnings of $2.18 per share, up 5% year over year. The figure was in line with the Zacks Consensus Estimate.
Revenues rose 13% year over year to $4.69 billion, surpassing the consensus estimate by 0.4%. Organic sales increased 7%. Volume growth accelerated to 2%, and pricing improved to 5%. Strong demand across Global High-Tech and Life Sciences supported the performance.
A Factor That May Offset ECL’s Gains
Cost Fluctuations: Ecolab continues to face cost pressures from elevated raw material, energy and transportation expenses, exacerbated by geopolitical disruptions in the Middle East. Although pricing improved to 5% in the third quarter from 4% in the preceding quarter, reported gross margin contracted 70 basis points year over year to 44.1%, while organic gross margin expanded just 10 basis points to 44.9%.
Management expects commodity costs to remain elevated and is relying on pricing actions, productivity gains and supply-chain efficiencies to offset inflation. For the fourth quarter of 2026, Ecolab expects an adjusted operating income margin of approximately 19% and an organic operating income margin of 20%. However, persistent cost inflation and delays in pricing recovery could weigh on profitability and limit further margin expansion.
Estimate Trend
Ecolab is witnessing a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for its earnings has remained stable at $8.16 per share.
The Zacks Consensus Estimate for the company’s fourth-quarter 2026 revenues is pegged at $4.75 billion, indicating a 13.1% improvement from the year-ago quarter’s reported number.
Key Picks
Some better-ranked stocks from the broader medical space are Glaukos (GKOS - Free Report) , Intuitive Surgical (ISRG - Free Report) and West Pharmaceutical Services (WST - Free Report) .
Glaukos, currently flaunting a Zacks Rank #1 (Strong Buy), reported third-quarter 2026 adjusted earnings per share (EPS) of 47 cents, which surpassed the Zacks Consensus Estimate by 491.7%. Revenues of $211 million beat the Zacks Consensus Estimate by 25%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GKOS has an estimated earnings growth rate of 155.6% for 2026. The company’s earnings beat estimates in three of the trailing four quarters and missed once, the average surprise being 138.6%.
Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported third-quarter 2026 adjusted EPS of $3.00, which beat the Zacks Consensus Estimate by 13.6%. Revenues of $3.05 billion surpassed the Zacks Consensus Estimate by 4.9%.
Intuitive Surgical has a long-term estimated growth rate of 15.5%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 15.1%.
West Pharmaceutical, currently carrying a Zacks Rank #2, reported a third-quarter 2026 adjusted EPS of $2.66, which surpassed the Zacks Consensus Estimate by 22%. Revenues of $874.5 million beat the Zacks Consensus Estimate by 5.9%.
WST has an estimated long-term earnings growth rate of 17.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 18.6%.